Related Experiment Video
Updated: Mar 19, 2026
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil1, Moritz Gerstung1, Lars Bullinger1
1Cancer Genome Project, Wellcome Trust Sanger Institute (E.P., M.G., N.D.R., N.B., G.G., P.V.L., I.M., L.M., S.M., S.O., K.R., D.R.J., J.W.T., A.P.B., P.J.C.), and the European Bioinformatics Institute, European Molecular Biology Laboratory (EMBL-EBI) (M.G.), Hinxton, the Centre for Evolution and Cancer, Institute of Cancer Research, London (N.E.P., M.F.G.), and the Department of Haematology, University of Cambridge, Cambridge (N.B.) - all in the United Kingdom; the Departments of Epidemiology and Biostatistics and Cancer Biology, the Center for Molecular Oncology and the Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York (E.P.); the Department of Internal Medicine III, Ulm University, Ulm (L.B., V.I.G., P.P., K.D., R.F.S., H.D.), and the Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Hannover (M.H., F.T., A.G.) - both in Germany; the Division of Hematology, Fondazione IRCCS, Istituto Nazionale dei Tumori, and Department of Oncology and Onco-Hematology, University of Milan, Milan (N.B.); the Department of Human Genetics, University of Leuven, Leuven, Belgium (P.V.L.); and the Department of Pathology, University of Otago, Christchurch, New Zealand (P.G., P.J.C.).
This study identifies distinct molecular subgroups in acute myeloid leukemia (AML) based on driver mutations, revealing new ways to classify and predict patient outcomes. Understanding these genetic patterns is key for personalized AML treatment strategies.
Area of Science:
- Genomics
- Oncology
- Hematology
Background:
- Recent advances have detailed gene mutations in acute myeloid leukemia (AML).
- The challenge lies in understanding how genetic diversity impacts AML pathophysiology and clinical care.
Purpose of the Study:
- To define AML genomic subgroups by integrating driver mutations, cytogenetic, and clinical data.
- To assess the relevance of these subgroups to clinical outcomes in a large patient cohort.
Main Methods:
- Analysis of 1540 patients from three prospective intensive therapy trials.
- Integration of driver mutations from 111 cancer genes with cytogenetic and clinical data.
- Genomic subgroup definition and outcome correlation.
Main Results:
- Identified 5234 driver mutations in 76 genes; 86% of patients had ≥2 drivers.
- Discovered 11 distinct genomic classes with unique features and outcomes.
- Highlighted three novel categories: chromatin-spliceosome (18%), TP53-aneuploidy (13%), and IDH2(R172) (1%) AML, with significant prognostic implications.
- Demonstrated additive effects of mutations and significant gene-gene interactions, particularly in NPM1-mutated AML, altering prognostic predictions.
Conclusions:
- The AML driver landscape reveals distinct molecular subgroups reflecting disease evolution.
- These findings inform improved disease classification and prognostic stratification for acute myeloid leukemia.
- Further validation in prospective clinical trials is warranted.
More Related Videos
09:01Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
Published on: March 26, 2018
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
